Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab with cyclophosphamide versus rituximab alone in ANCA-associated vasculitis
NL-OMON58674Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- May 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of rituximab and cyclophosphamide in anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Number of rituximab retreatment infusions needed to maintain clinical remission over 2 years. Started May 2019; status: recruiting.
02
Drugs
rituximabcyclophosphamide
03
Conditions
anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)
Beyond the preview
Go deeper on NL-OMON58674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58674.